Ori Biotech has developed the IRO® platform, a fully automated and standardized manufacturing system for cell and gene therapies that enhances biological performance while minimizing batch failures and reducing costs. This technology addresses the challenges of high manufacturing costs and low throughput, enabling scalable production and wider patient access to lifesaving treatments.
Funding
$140.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CIFounders
Product
Problem
Cell and gene therapies (CGTs) face significant manufacturing hurdles, including high costs, low throughput, batch failures, and a lack of reproducibility, which limit patient access to these potentially life-saving treatments. Traditional CGT manufacturing processes often require scientists to compromise biological performance for the sake of automation.
Solution
Ori Biotech offers the IRO® platform, an automated, standardized manufacturing system designed to address the challenges of CGT production and enable widespread patient access. The IRO® platform integrates superior biological performance with digitally-enabled automation to maximize clinical and commercial impact. By automating manual steps and deskilling processes, the platform enables high throughput, high quality, and lower-cost manufacturing. The cloud-native platform accelerates process development, reduces batch failures, and streamlines batch release, resulting in shorter development times and more efficient manufacturing.
Target Audience
Ori Biotech's primary customers are scientists and organizations involved in cell and gene therapy development and manufacturing, including CDMOs and commercial CGT manufacturers.
Features
- Fully automated and standardized manufacturing system for cell and gene therapies
- Digitally enabled automation to maximize clinical and commercial impact
- Biology-first approach to maintain cell quality, potency, and yield
- Cloud-native platform to accelerate process development
- Minimized batch failures and streamlined batch release
- Capability to automate manual steps and deskill processes